InvestorsHub Logo
Followers 7
Posts 292
Boards Moderated 0
Alias Born 08/03/2020

Re: None

Monday, 01/11/2021 1:45:59 PM

Monday, January 11, 2021 1:45:59 PM

Post# of 44690
Someone tell me I'm wrong. But if I read the PR again. It reads to me like it has been cleverly worded to make it sounded like HHS and DOD asked Relief to participate in this. But if you read carefully it just says that they put out a public statement saying that treatments for critically ill was a big need. Also the I-spy website is horribly outdated and doesn't mention any of this, nor their link with HHS or DOD.

Read these two paragraphs. I'd be happy to be wrong.

The inclusion of ZYESAMI™ in the I-SPY COVID-19 Trial follows a request from the U.S. Department of Health and Human Services and the Department of Defense for investigational drugs capable of targeting the most acutely ill patients with COVID-19. ZYESAMI™ has been granted Fast Track designation by the U.S. Food & Drug Administration (FDA) for the treatment of Critical COVID-19 in patients with Respiratory Failure.

In December 2020, Dr. Robert Kadlec, HHS Assistant Secretary for Preparedness and Response, issued a public statement that "Through our Operation Warp Speed partnership, we have worked feverishly with private industry to develop and make treatments available to reduce hospitalization, either shortening the length of stay or treating people with mild or moderate COVID-19 infections before they have to be hospitalized. While we're making significant progress, treatments to save lives of the sickest patients, such as patients in intensive care or on ventilators, remain an urgent need."